Elixir Associates reposted this
Genentech going through a major shift. Famous cell biologist Ira Mellman is leaving after 17 great years, causing the cancer immunology research department to close. This part will join with the molecular oncology team to create a combined cancer research group in Genentech Research and Early Development (gRED). Mellman's big contributions to cancer immunology, like his important work on endosomes and new cancer treatments, have made a lasting impact. His exit marks the end of an important era. Genentech says this restructure is a smart move to take advantage of new scientific opportunities, and it doesn't mean they're less committed to cancer immunology. The company is still focused on blending immunotherapy with their larger cancer research efforts. These changes come at a tough time for Genentech's cancer immunotherapy projects, with challenges in the anti-TIGIT program and shifts in other priorities. #CancerResearch #Biotechnology #LifeSciences
